Alector licenses AL050 GCase program to Genentech for $100M upfront plus $1.17B milestones

Alector granted Genentech exclusive worldwide rights to develop and commercialize its AL050 brain-penetrant glucocerebrosidase enzyme replacement therapy, with Alector receiving $100 million upfront and up to $1.17 billion in development, regulatory, and commercial milestone payments plus tiered royalties on net sales. This represents a significant licensing transaction monetizing a key pipeline asset, though the upfront payment is moderate relative to a biotech's market cap and the deal retains Alector's platform for other applications.

Alector licensed its AL050 brain therapy candidate to Genentech (a major pharma company) for $100 million now, plus potential payments later if development succeeds. This validates the program and gives Alector cash while Genentech takes on development costs.